PTCT News Alert Ptc Therapeutics Inc (PTCT) 51.66 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ptc Therapeutics Inc (PTCT) 51.66 $PTCT

PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PTCT: 51.66 (+0.76), BIOD: 1.36 (-0.04)

PTC Therapeutics begins rolling submission of Translarna's NDA to the US FDA for treating nonsense mutation Duchenne muscular dystrophy
M2 - Wed Dec 24, 3:46AM CST
Biopharmaceutical company PTC Therapeutics (NasdaqGS TCT) reported on Tuesday the initiation of a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
PTCT: 51.66 (+0.76)

BioMarin CEO Sees Big Future For Prosensa Drug
at Investor's Business Daily - Tue Dec 23, 3:11PM CST
BioMarin Pharmaceuticals raised a few eyebrows last month when it announced its latest buyout. BioMarin (BMRN) agreed to pay $680 million upfront for Prosensa Holding (RNA), a Dutch biotech developing a drug for Duchenne muscular dystrophy called...
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)

PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST

ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), PTCT: 51.66 (+0.76)

PTC Therapeutics Begins Rolling NDA Submission to the FDA for Translarna to Treat Duchenne Muscular Dystrophy
PR Newswire - Tue Dec 23, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna(TM) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. PTC expects to finalize the application in the fourth quarter of 2015 following the completion of the ACT DMD confirmatory Phase 3 clinical trial.
PTCT: 51.66 (+0.76)

3 Drugmakers Facing a Pivotal 2015
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 10:41AM CST
Source: www.bio.org Pharmaceutical companies have been some of the best performing stocks lately due to the confluence of an aging U.S. population and new regulatory avenues within the Food and Drug Administration that have led to an uptick in drug...
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), GWPH: 68.08 (+1.82), AZN: 70.44 (+0.26), IBB: 299.80 (+5.12), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)

PTC Therapeutics (PTCT) Downgraded From Hold to Sell
at The Street - Mon Dec 22, 10:40AM CST
PTC Therapeutics (PTCT) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+. 
PTCT: 51.66 (+0.76)

Translarna tagged an Orphan Drug for MPS 1 in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 12:39PM CST

PTCT: 51.66 (+0.76)

Translarna Granted Orphan Drug Designation in the U.S. and Europe for the Treatment of Mucopolysaccharidosis I
PR Newswire - Fri Dec 19, 7:00AM CST
PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan-drug designation (ODD) to Translarna(TM) (ataluren) for the treatment of patients with Mucopolysaccharidosis I (MPS I). MPS I is an inherited genetic disorder caused by a deficiency in an essential enzyme that is responsible for the breakdown of by-products in the body's cells. There is significant unmet medical need and new treatments targeting the underlying cause of the disease are needed. MPS I represents the third indication for which Translarna has received orphan-drug designation. Translarna also has orphan-drug designation for Duchenne muscular dystrophy and cystic fibrosis.
PTCT: 51.66 (+0.76)

PTC Therapeutics awards stock options to ten new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Thu Dec 18, 7:12AM CST
Biopharmaceutical company PTC Therapeutics (NasdaqGS TCT) Wednesday authorised the grant of non-statutory stock options to purchase an aggregate of 46,750 shares of its common stock to ten new employees in accordance with NASDAQ Listing Rule 5635(c)(4).
PTCT: 51.66 (+0.76)

Chimerix appoints Ronald C. Renaud Jr to board
M2 - Thu Dec 18, 7:12AM CST
Biopharmaceutical company Chimerix (NasdaqGM:CMRX) revealed on Wednesday the addition of Ronald C. Renaud Jr to its board of directors.
CMRX: 36.80 (+0.70), PTCT: 51.66 (+0.76)

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Wed Dec 17, 3:30PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2014 it approved non-statutory stock options to purchase an aggregate of 46,750 shares of its common stock to ten new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of its new hires' employment compensation.
PTCT: 51.66 (+0.76)

Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:10AM CST

ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), PTCT: 51.66 (+0.76)

Why PTC Therapeutics (PTCT) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:31AM CST
PTC Therapeutics (PTCT) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 72 out of more than 250 industries.
PTCT: 51.66 (+0.76)

PTC Therapeutics, Inc. (PTCT) in Focus: Stock Gains 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:32AM CST
PTC Therapeutics, Inc. (PTCT) was a big mover last session, as the company saw its shares rise more than 5% on the day.
LGI: 16.17 (-0.01), ARQL: 1.15 (+0.01), PTCT: 51.66 (+0.76), IG: 9.11 (-0.01)

PTC Therapeutics Announces Launch of Translarna(TM) (ataluren) in Germany
PR Newswire - Wed Dec 03, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna(TM) (ataluren) is now commercially available to patients in Germany, the first country to launch in the European Union (EU), with first shipments expected to begin this week.
PTCT: 51.66 (+0.76)

PTC Therapeutics (PTCT) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 5:40AM CST
PTC Therapeutics (PTCT) Shares March Higher, Can It Continue?
PTCT: 51.66 (+0.76)

Catabasis Pharmaceuticals' CAT-1004 tagged an Orphan Drug for DMD
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:15AM CST

ROSG: 2.35 (+0.03), BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PTCT: 51.66 (+0.76)

PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award
PR Newswire - Fri Nov 21, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that the 2014 Legend of Technology Award for Vision, Innovation, and Leadership has been awarded to Stuart W. Peltz, Ph.D., Chief Executive Officer. This award recognizes an individual who has had a significant impact on the technology industry in New Jersey for several decades.
PTCT: 51.66 (+0.76)

Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial in Patients with SMA
PR Newswire - Wed Nov 19, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) has started a Phase 1b/2a study in adult and pediatric patients. The placebo-controlled, randomized, multiple-dose study will enroll approximately 48 patients with SMA and investigate the safety and tolerability of an investigational survival of motor neuron 2 (SMN2) gene splicing modifier (RG7800) over 12 weeks. The achievement of this milestone triggers a $10 million payment to PTC from Roche.
PTCT: 51.66 (+0.76)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 17

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading
Saban Center Partnership Gives Health Learning a Lift

Updated Category News Views 45

A dinosaur race may sound like pure kid bait, but the underlying idea is sturdier than that. Cardiac Solutions and the Seale family are backing an interactive health-and-performance exhibit at Tuscaloosa’s planned Saban Center, a project intended to turn questions about movement, fitness, heart rate and oxygen levels into something children can actually touch, test and...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 138

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
FLX Opens a New Door to Pre-IPO Deal Flow for Advisors

Updated Category News Views 126

Private-market chatter has been leaking past the velvet rope for years, and advisors are sick of learning about it after a client already has a pitch deck in hand. FLX Networks is responding to that irritation by letting its eligible advisor and wealth-management members review select pre-IPO opportunities shared by other members. Announced November 19, 2026, the move is...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 164

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 110

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
CMA Wins Spotlight Greenberg Traurig’s Music Bench

Updated Category News Views 81

Four trophies on one awards night can say plenty about the machinery behind a music career, even if nobody should confuse a CMA acceptance speech with a balance-sheet event. Greenberg Traurig’s entertainment practice is celebrating client wins at the 60th annual CMA Awards, held Nov. 18, 2026: three honors tied to Miranda Lambert and one for Brooks & Dunn. For investors...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 47

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 118

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading

Top 5 Most Recently Viewed Articles

Eastman Chemical’s Stock Surge Marks a Turning Point for Investors

Updated Category News Views 82

Eastman Chemical's Stock Hits New Heights Eastman Chemical Company (NYSE: EMN) has recently reached an impressive milestone, with its stock price climbing to a 52-week high of $107.14. This significant price point reflects growing investor confidence and a positive market outlook for the company. With a remarkable 34.6% increase over the past year, Eastman Chemical has...

Continue Reading
BOS Expands Automation Solutions with New System Orders

Updated Category News Views 270

BOS Secures New Orders for Robotic Solutions BOS Better Online Solutions Ltd. (NASDAQ: BOSC), renowned for its expertise in supply chain technologies, has recently announced a significant milestone. The company secured orders for two innovative robotic packing and palletizing systems aimed at enhancing efficiency in food manufacturing. Details of the New Orders These new...

Continue Reading
Amazon's Cloud and AI Strategy Set to Shape Future Growth

Updated Category News Views 260

Overview Amazon.com, Inc. (NASDAQ: AMZN) plays a crucial role in the realms of e-commerce, cloud computing, digital streaming, and artificial intelligence. Recent analyses from respected financial institutions provide a thorough insight into Amazon's market performance, strategic initiatives, and its future outlook. This article brings together these evaluations, zeroing...

Continue Reading
WTW's Strategic Acquisitions: A Leap into the Future of Insurance

Updated Category News Views 211

WTW Expands Through Innovative Acquisitions Willis Towers Watson Public Ltd., known as WTW, is making headlines with its ambitious strategy to enhance its technology-enabled insurance and workplace benefits services. By announcing two consequential acquisitions, WTW aims to broaden its reach in the middle market while modernizing its client interactions significantly....

Continue Reading
Genmab's Share Buy-Back Program: Recent Transaction Details

Updated Category News Views 173

Introduction to Genmab Genmab A/S is a pioneering biotechnology company based in Copenhagen, Denmark, dedicated to improving the lives of patients through innovative antibody therapies. Founded in 1999, Genmab has continuously worked on developing groundbreaking antibody technology platforms, aiming to advance treatment for serious diseases such as cancer. Share Buy-Back...

Continue Reading